Peptides Similar to Exenatide
Compare Exenatide with related peptides and alternatives
📌TL;DR
- •3 similar peptides identified
- •Semaglutide: High - Both are injectable GLP-1 receptor agonists approved for T2D with once-weekly formulations available
- •Liraglutide: High - Both are injectable GLP-1 receptor agonists for T2D, liraglutide is the next GLP-1 RA approved after exenatide
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| Exenatide (current) | - | - |
| Semaglutide | High - Both are injectable GLP-1 receptor agonists approved for T2D with once-weekly formulations available | Semaglutide is a human GLP-1 analog (97% homology) with C18 fatty diacid for albumin binding, while exenatide is a reptilian exendin-4 peptide (53% homology) with no lipid modification. Fundamentally different molecular strategies for the same receptor target. |
| Liraglutide | High - Both are injectable GLP-1 receptor agonists for T2D, liraglutide is the next GLP-1 RA approved after exenatide | Liraglutide is a human GLP-1 analog (97% homology) with C16 fatty acid for once-daily dosing. Exenatide is exendin-4 with twice-daily (Byetta) or once-weekly microsphere (Bydureon) dosing. |
| Tirzepatide | Moderate - Both are injectable incretin-based therapies for T2D with once-weekly dosing | Tirzepatide is a dual GIP/GLP-1 receptor agonist (39 amino acids, GIP backbone), while exenatide is a selective GLP-1 agonist (39 amino acids, exendin-4 backbone). Both are 39 residues but entirely different sequences. |
SemaglutideHigh - Both are injectable GLP-1 receptor agonists approved for T2D with once-weekly formulations available
Differences
Semaglutide is a human GLP-1 analog (97% homology) with C18 fatty diacid for albumin binding, while exenatide is a reptilian exendin-4 peptide (53% homology) with no lipid modification. Fundamentally different molecular strategies for the same receptor target.
Advantages
Vastly superior HbA1c reduction and weight loss, proven CV benefit (SELECT trial), lower immunogenicity, oral formulation (Rybelsus), approved for obesity
Disadvantages
Higher cost, shorter market track record than exenatide, no unique neuroprotection research
LiraglutideHigh - Both are injectable GLP-1 receptor agonists for T2D, liraglutide is the next GLP-1 RA approved after exenatide
Differences
Liraglutide is a human GLP-1 analog (97% homology) with C16 fatty acid for once-daily dosing. Exenatide is exendin-4 with twice-daily (Byetta) or once-weekly microsphere (Bydureon) dosing.
Advantages
Superior HbA1c and weight loss (LEAD-6 head-to-head), proven CV benefit (LEADER), lower immunogenicity, approved for obesity (Saxenda) and adolescent obesity, generic available (2025)
Disadvantages
Daily injection required (vs exenatide weekly), higher cost than exenatide (though generic available)
TirzepatideModerate - Both are injectable incretin-based therapies for T2D with once-weekly dosing
Differences
Tirzepatide is a dual GIP/GLP-1 receptor agonist (39 amino acids, GIP backbone), while exenatide is a selective GLP-1 agonist (39 amino acids, exendin-4 backbone). Both are 39 residues but entirely different sequences.
Advantages
Greatest weight loss and HbA1c reduction of any approved agent, dual receptor mechanism, once-weekly dosing
Disadvantages
Much higher cost, shorter safety track record (approved 2022 vs 2005), no proven CV outcomes yet, no neuroprotection research
Peptides Related to Exenatide#
Exenatide holds a unique position in the GLP-1 receptor agonist class as the founding member, the first agent approved (2005), and the only one derived from a non-human source (Gila monster venom). While superseded by newer agents in glycemic efficacy and weight loss, exenatide established the proof-of-concept for the entire incretin mimetic drug class and maintains a distinctive research profile in neurodegeneration.
Semaglutide (Ozempic / Wegovy / Rybelsus)#
Semaglutide represents the current state-of-the-art in selective GLP-1 receptor agonism.
Molecular comparison: Exenatide is a 39-amino-acid reptilian peptide (exendin-4, 53% GLP-1 homology) with no lipid modification, while semaglutide is a 31-amino-acid human GLP-1 analog (97% homology) with an Aib2 substitution and C18 fatty diacid for albumin binding. Both achieve DPP-4 resistance but through entirely different strategies: exenatide through natural Gly2 substitution, semaglutide through engineered Aib2.
Clinical efficacy: Semaglutide is dramatically more efficacious. In the SUSTAIN-3 head-to-head trial, semaglutide 1 mg weekly achieved -1.5% HbA1c reduction versus -0.9% with exenatide 2 mg weekly, and -5.6 kg weight loss versus -1.9 kg. For obesity, semaglutide 2.4 mg achieves 14.9% weight loss (STEP 1) compared to approximately 2-3% with exenatide.
Cardiovascular outcomes: Semaglutide has demonstrated cardiovascular superiority in both SUSTAIN-6 (26% MACE reduction in T2D) and SELECT (20% MACE reduction in non-diabetic obesity). Exenatide achieved only cardiovascular safety (EXSCEL: HR 0.91, P=0.06 for superiority).
Practical considerations: Semaglutide offers once-weekly injection, oral formulation (Rybelsus), and multiple approved indications (T2D, obesity, CV risk reduction). Exenatide offers the longest safety track record (since 2005) and unique neuroprotection research.
| Parameter | Exenatide | Semaglutide |
|---|---|---|
| Molecular origin | Gila monster exendin-4 | Human GLP-1 analog |
| GLP-1 homology | 53% | 97% |
| Dosing | BID (Byetta) / QW (Bydureon) | QW (SC) / QD (oral) |
| HbA1c reduction | 0.8-1.9% | 1.5-2.2% |
| Weight loss | 2-3% | 14.9-16% |
| CV outcomes | Neutral (safety) | Positive (superiority) |
| Immunogenicity | 38-64% ADA | <1% ADA |
| Market since | 2005 | 2017 |
| Neuroprotection research | Yes (Parkinson's) | Investigational |
Liraglutide (Victoza / Saxenda)#
Liraglutide was the second major GLP-1 RA to market (2010), representing the transition from exendin-4-based to human GLP-1-based agents.
LEAD-6 head-to-head: Liraglutide 1.8 mg daily was directly compared to exenatide 10 mcg BID over 26 weeks. Liraglutide achieved superior HbA1c reduction (-1.1% vs -0.8%) with greater fasting glucose lowering and comparable weight loss. This trial established the efficacy hierarchy.
Key differences: Liraglutide requires daily injection but offers obesity approval (Saxenda 3.0 mg), adolescent obesity approval, proven cardiovascular benefit (LEADER: 13% MACE reduction), and generic availability since 2025. Exenatide offers once-weekly dosing (Bydureon) and the longest safety record.
Tirzepatide (Mounjaro / Zepbound)#
Tirzepatide represents the newest evolution: dual GIP/GLP-1 receptor agonism.
Efficacy comparison: Tirzepatide produces the greatest weight loss (20.9-22.5% in SURMOUNT-1) and HbA1c reduction (up to -2.58% in SURPASS trials) of any approved agent. This dramatically exceeds exenatide's modest efficacy.
Key trade-off: Tirzepatide's vastly superior efficacy comes with a much shorter safety record (approved 2022 vs 2005) and pending cardiovascular outcomes data.
Dulaglutide (Trulicity)#
Dulaglutide is another once-weekly GLP-1 RA, with a unique IgG4-Fc fusion protein design.
Comparison: Dulaglutide offers simpler injection (pre-filled single-dose pen), once-weekly dosing, and proven CV benefit (REWIND: 12% MACE reduction). Its efficacy is intermediate between exenatide and semaglutide. Dulaglutide has been the most prescribed GLP-1 RA by volume in several markets.
Summary Comparison#
| Feature | Exenatide | Liraglutide | Semaglutide | Tirzepatide |
|---|---|---|---|---|
| Receptor targets | GLP-1 | GLP-1 | GLP-1 | GIP + GLP-1 |
| Molecular origin | Exendin-4 (reptilian) | Human GLP-1 analog | Human GLP-1 analog | GIP-based chimera |
| Dosing | BID SC / QW SC | QD SC | QW SC / QD oral | QW SC |
| HbA1c reduction | 0.8-1.9% | 1.0-1.5% | 1.5-2.2% | 1.87-2.58% |
| Weight loss | 2-3% | 8.0% | 14.9-16% | 20.9-22.5% |
| CV outcomes | Neutral | Positive | Positive | Pending |
| Obesity indication | No | Yes (Saxenda) | Yes (Wegovy) | Yes (Zepbound) |
| Market since | 2005 | 2010 | 2017 | 2022 |
| Neuroprotection | Parkinson's research | Not studied | Investigational | Not studied |
Exenatide's Remaining Clinical Niche#
Despite being surpassed in metabolic efficacy, exenatide retains relevance in several contexts:
- Longest safety record: Nearly 20 years of market experience may be valuable for risk-averse clinical scenarios
- Parkinson's disease research: Unique neuroprotection data not shared by other approved GLP-1 agents
- Cost considerations: As one of the older GLP-1 agents, pricing may be more accessible in some markets
- Formulary constraints: In some healthcare systems, exenatide may be the available GLP-1 option due to formulary restrictions
Related Reading#
Frequently Asked Questions About Exenatide
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer